The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Geary, Sean M ^a   Lemke, Caitlin D ^a   Lubaroff, David M ^b   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLUOROURACIL; OVALBUMIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOMODULATION; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; SPLEEN; SUPPRESSOR CELL; SURVIVAL RATE; T CELL DEPLETION; TUMOR MODEL; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DRUG SYNERGISM; FLUOROURACIL; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; SPLEEN; SURVIVAL RATE;

ADENOVIRIDAE; MUS;

EID: 84879525182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067904     Document Type: Article

References (42)

1. (2012) Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
2. Longley DB, Johnston PG, (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
3. Lu P, (2005) Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 35: 197-201.
4. Tipton JM (2003) Side effects of cancer chemotherapy. In: Skeel RT, editor. Handbook of Cancer Chemotherapy. Philadelphia: Lippincott Williams & Wilkins. 561-580.
5. Krishnamachari Y, Geary SM, Lemke CD, Salem AK, (2011) Nanoparticle delivery systems in cancer vaccines. Pharm Res 28: 215-236.
6. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, et al. (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112: 610-618.
7. Liniger M, Zuniga A, Naim HY, (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6: 255-266.
8. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, et al. (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3: e25.
9. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP, (2002) Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 62: 5260-5266.
10. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM, (2001) Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 94: 842-849.
11. Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, et al. (2001) Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 166: 731-735.
12. Geary SM, Lemke CD, Lubaroff DM, Salem AK, (2011) Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother 60: 1309-1317.
13. Amato RJ, (2010) 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 10: 281-287.
14. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR, (2012) The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 39: 323-339.
15. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, et al. (2008) Next generation of immunotherapy for melanoma. J Clin Oncol 26: 3445-3455.
16. Pardoll DM, (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
17. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, et al. (2010) Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 18: 1947-1959.
18. Nowak AK, Lake RA, Robinson BW, (2006) Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58: 975-990.
19. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, et al. (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878-887.
20. Bass KK, Mastrangelo MJ, (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47: 1-12.
21. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, et al. (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.
22. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM, (1996) Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19: 309-316.
23. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, et al. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70: 3052-3061.
24. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, et al. (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790.
25. Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, et al. (2011) Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41: 2217-2228.
26. Moore MW, Carbone FR, Bevan MJ, (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
27. Ooboshi H, Chu Y, Rios CD, Faraci FM, Davidson BL, et al. (1997) Altered vascular function after adenovirus-mediated overexpression of endothelial nitric oxide synthase. Am J Physiol 273: H265-270.
28. Karan D, Krieg AM, Lubaroff DM, (2007) Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 121: 1520-1528.
29. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
30. Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, et al. (1992) Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Int J Radiat Oncol Biol Phys 22: 511-514.
31. Morales JK, Kmieciak M, Graham L, Feldmesser M, Bear HD, et al. (2009) Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 58: 941-953.
32. Matsuzaki J, Tsuji T, Chamoto K, Takeshima T, Sendo F, et al. (2003) Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo. Cell Immunol 224: 98-105.
33. Tvinnereim AR, Hamilton SE, Harty JT, (2004) Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol 173: 1994-2002.
34. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, et al. (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67: 7477-7486.
35. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
36. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802.
37. Mauti LA, Le Bitoux MA, Baumer K, Stehle JC, Golshayan D, et al. (2011) Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J Clin Invest 121: 2794-2807.
38. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, et al. (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 7: e40677.
39. Backus HH, Dukers DF, van Groeningen CJ, Vos W, Bloemena E, et al. (2001) 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 12: 209-216.
40. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, et al. (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697.
41. Garnett CT, Schlom J, Hodge JW, (2008) Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14: 3536-3544.
42. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, et al. (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27: 5911-5918.